NO20065512L - O-bundne gykoformer av polypeptider og fremgangsmater for deres fremstilling. - Google Patents

O-bundne gykoformer av polypeptider og fremgangsmater for deres fremstilling.

Info

Publication number
NO20065512L
NO20065512L NO20065512A NO20065512A NO20065512L NO 20065512 L NO20065512 L NO 20065512L NO 20065512 A NO20065512 A NO 20065512A NO 20065512 A NO20065512 A NO 20065512A NO 20065512 L NO20065512 L NO 20065512L
Authority
NO
Norway
Prior art keywords
methods
linked
gycoforms
polypeptides
preparation
Prior art date
Application number
NO20065512A
Other languages
English (en)
Inventor
Niels Kristian Klausen
Daniel Rasmussen
Original Assignee
Novo Nordisk Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34968774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20065512(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk Healthcare Ag filed Critical Novo Nordisk Healthcare Ag
Publication of NO20065512L publication Critical patent/NO20065512L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Den foreliggende oppfinnelsen angår sammensetninger som omfatter glykoproteiner som har et endret mønster av 0-bundet glykosylering, spesielt faktor VII, faktor IX og fremgangsmåter for fremstilling av disse.
NO20065512A 2004-05-04 2006-11-29 O-bundne gykoformer av polypeptider og fremgangsmater for deres fremstilling. NO20065512L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200400712 2004-05-04
DKPA200400882 2004-06-04
PCT/EP2005/052024 WO2005111225A1 (en) 2004-05-04 2005-05-03 O-linked glycoforms of polypeptides and method to manufacture them

Publications (1)

Publication Number Publication Date
NO20065512L true NO20065512L (no) 2006-11-29

Family

ID=34968774

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065512A NO20065512L (no) 2004-05-04 2006-11-29 O-bundne gykoformer av polypeptider og fremgangsmater for deres fremstilling.

Country Status (15)

Country Link
US (3) US20080305518A1 (no)
EP (1) EP1745141B2 (no)
JP (2) JP5826446B2 (no)
KR (1) KR20070008645A (no)
AT (1) ATE455861T1 (no)
AU (1) AU2005243427B2 (no)
BR (1) BRPI0510295A (no)
CA (1) CA2565414A1 (no)
DE (1) DE602005019038D1 (no)
ES (1) ES2339953T5 (no)
IL (1) IL178541A0 (no)
MX (1) MXPA06012676A (no)
NO (1) NO20065512L (no)
RU (1) RU2006138181A (no)
WO (1) WO2005111225A1 (no)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7157277B2 (en) * 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
ES2420581T3 (es) 2003-03-14 2013-08-26 Biogenerix Gmbh Polímeros solubles en agua ramificados y sus conjugados
EP1615945B1 (en) 2003-04-09 2011-09-28 BioGeneriX AG Glycopegylation methods and proteins/peptides produced by the methods
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
WO2004103275A2 (en) 2003-05-09 2004-12-02 Neose Technologies, Inc. Compositions and methods for the preparation of human growth hormone glycosylation mutants
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
JP5743368B2 (ja) 2004-01-08 2015-07-01 ラショファーム ゲーエムベーハー ペプチドのｏ結合型グリコシル化
DE602005019038D1 (de) 2004-05-04 2010-03-11 Novo Nordisk Healthcare Ag O-verknüpfte glykoformen von faktor vii und verfahren zu deren herstellung
US20080300173A1 (en) * 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
EP1799249A2 (en) 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegylated interferon alpha
US20080176790A1 (en) 2004-10-29 2008-07-24 Defrees Shawn Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US20070154992A1 (en) 2005-04-08 2007-07-05 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
JP5216580B2 (ja) 2005-05-25 2013-06-19 ノヴォ ノルディスク アー／エス グリコペグ化第ｉｘ因子
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
CN101268185B (zh) * 2005-09-01 2013-03-27 诺沃-诺迪斯克保健股份有限公司 因子ⅶ多肽的疏水作用色谱纯化
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
KR101492422B1 (ko) * 2006-04-11 2015-02-12 체에스엘 베링 게엠베하 치료용 폴리펩타이드의 생체내 회수율을 증가시키는 방법
US20080242607A1 (en) 2006-07-21 2008-10-02 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
WO2008033517A2 (en) 2006-09-13 2008-03-20 Abbott Laboratories Cell culture improvements
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
US20100075375A1 (en) 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
JP5448839B2 (ja) 2006-12-22 2014-03-19 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー インビボで長い半減期を有する修飾された凝固因子
KR20100016160A (ko) 2007-04-03 2010-02-12 바이오제너릭스 에이지 글리코페길화 ｇ―ｃｓｆ를 이용하는 치료 방법
MX2009013259A (es) 2007-06-12 2010-01-25 Novo Nordisk As Proceso mejorado para la produccion de azucares de nucleotidos.
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
US20110154516A1 (en) * 2007-10-15 2011-06-23 Stafford Darrel W Human factor ix variants with an extended half life
US20130189239A1 (en) 2008-02-27 2013-07-25 Novo Nordisk A/S Conjugated Factor VIII Molecules
TWI538916B (zh) 2008-04-11 2016-06-21 介控生化科技公司 經修飾的因子vii多肽和其用途
US20100130811A1 (en) * 2008-04-24 2010-05-27 Searete Llc Computational system and method for memory modification
US9449150B2 (en) 2008-04-24 2016-09-20 The Invention Science Fund I, Llc Combination treatment selection methods and systems
US9662391B2 (en) 2008-04-24 2017-05-30 The Invention Science Fund I Llc Side effect ameliorating combination therapeutic products and systems
US8606592B2 (en) 2008-04-24 2013-12-10 The Invention Science Fund I, Llc Methods and systems for monitoring bioactive agent use
US9026369B2 (en) 2008-04-24 2015-05-05 The Invention Science Fund I, Llc Methods and systems for presenting a combination treatment
US8682687B2 (en) * 2008-04-24 2014-03-25 The Invention Science Fund I, Llc Methods and systems for presenting a combination treatment
US20100069724A1 (en) * 2008-04-24 2010-03-18 Searete Llc Computational system and method for memory modification
US8876688B2 (en) 2008-04-24 2014-11-04 The Invention Science Fund I, Llc Combination treatment modification methods and systems
US8615407B2 (en) 2008-04-24 2013-12-24 The Invention Science Fund I, Llc Methods and systems for detecting a bioactive agent effect
US9649469B2 (en) 2008-04-24 2017-05-16 The Invention Science Fund I Llc Methods and systems for presenting a combination treatment
US8930208B2 (en) 2008-04-24 2015-01-06 The Invention Science Fund I, Llc Methods and systems for detecting a bioactive agent effect
US9239906B2 (en) 2008-04-24 2016-01-19 The Invention Science Fund I, Llc Combination treatment selection methods and systems
US9282927B2 (en) 2008-04-24 2016-03-15 Invention Science Fund I, Llc Methods and systems for modifying bioactive agent use
US9560967B2 (en) 2008-04-24 2017-02-07 The Invention Science Fund I Llc Systems and apparatus for measuring a bioactive agent effect
US9064036B2 (en) 2008-04-24 2015-06-23 The Invention Science Fund I, Llc Methods and systems for monitoring bioactive agent use
EP2921501A1 (en) 2008-10-20 2015-09-23 Abbvie Inc. Isolation and purification of antibodies using Protein A affinity chromatography
CN104974251A (zh) 2008-10-20 2015-10-14 Abbvie公司 在抗体纯化过程中的病毒灭活
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
WO2014035475A1 (en) 2012-09-02 2014-03-06 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
EP2983701A2 (en) * 2013-03-11 2016-02-17 Genzyme Corporation Site-specific antibody-drug conjugation through glycoengineering
AU2013381687A1 (en) 2013-03-12 2015-09-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9175279B1 (en) 2013-03-15 2015-11-03 Csl Limited Method of purifying factor VII and/or factor VIIa
SG11201601823TA (en) 2013-09-13 2016-04-28 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
PL3129067T3 (pl) 2014-03-19 2023-05-08 Genzyme Corporation Specyficzne dla miejsca glikomodyfikowanie ugrupowań celujących
MX2017004664A (es) 2014-10-09 2017-06-30 Genzyme Corp Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria.
ES2842523T3 (es) 2015-05-15 2021-07-14 Univ Michigan Regents Métodos y composiciones para el tratamiento de la artritis
US20210069306A1 (en) 2019-08-15 2021-03-11 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479268A (en) * 1973-07-05 1977-07-13 Beecham Group Ltd Pharmaceutical compositions
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
CH596313A5 (no) * 1975-05-30 1978-03-15 Battelle Memorial Institute
US4385260A (en) * 1975-09-09 1983-05-24 Beckman Instruments, Inc. Bargraph display
US4414147A (en) * 1981-04-17 1983-11-08 Massachusetts Institute Of Technology Methods of decreasing the hydrophobicity of fibroblast and other interferons
JPS57206622A (en) * 1981-06-10 1982-12-18 Ajinomoto Co Inc Blood substitute
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
WO1987000056A1 (en) 1985-06-26 1987-01-15 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JPS6238172A (ja) * 1985-08-12 1987-02-19 株式会社　高研 抗血栓性医用材料の製造方法
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
US4925796A (en) * 1986-03-07 1990-05-15 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US6166183A (en) * 1992-11-30 2000-12-26 Kirin-Amgen, Inc. Chemically-modified G-CSF
DE68929551T2 (de) 1988-12-23 2008-03-06 Genentech, Inc., South San Francisco Menschliche DNase
US5182107A (en) * 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5672683A (en) 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US5527527A (en) * 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5154924A (en) * 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
DE4009630C2 (de) * 1990-03-26 1995-09-28 Reinhard Prof Dr Dr Brossmer CMP-aktivierte fluoreszierende Sialinsäuren sowie Verfahren zu ihrer Herstellung
US5212075A (en) 1991-04-15 1993-05-18 The Regents Of The University Of California Compositions and methods for introducing effectors to pathogens and cells
US5352670A (en) * 1991-06-10 1994-10-04 Alberta Research Council Methods for the enzymatic synthesis of alpha-sialylated oligosaccharide glycosides
US6037452A (en) * 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
WO1994005332A2 (en) 1992-09-01 1994-03-17 Berlex Laboratories, Inc. Glycolation of glycosylated macromolecules
WO1994015625A1 (en) 1993-01-15 1994-07-21 Enzon, Inc. Factor viii - polymeric conjugates
US5374541A (en) * 1993-05-04 1994-12-20 The Scripps Research Institute Combined use of β-galactosidase and sialyltransferase coupled with in situ regeneration of CMP-sialic acid for one pot synthesis of oligosaccharides
US5621039A (en) * 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
SE9304316D0 (sv) * 1993-12-24 1993-12-24 Kurt Nilsson Aminosyra-konjugat
US5432059A (en) * 1994-04-01 1995-07-11 Specialty Laboratories, Inc. Assay for glycosylation deficiency disorders
EP0779932B1 (en) * 1994-09-06 2000-08-02 Ab Bioflexin Amino acid conjugate
US5545553A (en) * 1994-09-26 1996-08-13 The Rockefeller University Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
US5834251A (en) * 1994-12-30 1998-11-10 Alko Group Ltd. Methods of modifying carbohydrate moieties
US5922577A (en) * 1995-04-11 1999-07-13 Cytel Corporation Enzymatic synthesis of glycosidic linkages
US5876980A (en) * 1995-04-11 1999-03-02 Cytel Corporation Enzymatic synthesis of oligosaccharides
US5728554A (en) * 1995-04-11 1998-03-17 Cytel Corporation Enzymatic synthesis of glycosidic linkages
US6030815A (en) * 1995-04-11 2000-02-29 Neose Technologies, Inc. Enzymatic synthesis of oligosaccharides
US6015555A (en) * 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
AU6255096A (en) 1995-06-07 1996-12-30 Mount Sinai School Of Medicine Of The City University Of New York, The Pegylated modified proteins
DE19531637A1 (de) * 1995-08-28 1997-03-06 Immuno Ag Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung
US5716812A (en) * 1995-12-12 1998-02-10 The University Of British Columbia Methods and compositions for synthesis of oligosaccharides, and the products formed thereby
TWI240627B (en) 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
AU736993B2 (en) 1997-01-16 2001-08-09 Novo Nordisk A/S Practical in vitro sialylation of recombinant glycoproteins
US6183738B1 (en) * 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
AT407255B (de) * 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
EP0994903B1 (en) 1997-06-24 2005-05-25 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
AU8269898A (en) 1997-06-27 1999-01-19 Regents Of The University Of California, The Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor
WO2001082943A2 (en) 2000-05-03 2001-11-08 Novo Nordisk A/S Subcutaneous administration of coagulation factor vii
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
AT408613B (de) 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
DE19852729A1 (de) * 1998-11-16 2000-05-18 Werner Reutter Rekombinante Glycoproteine, Verfahren zu ihrer Herstellung, sie enthaltende Arzneimittel und ihre Verwendung
JP4635340B2 (ja) 1999-05-31 2011-02-23 三菱化学株式会社 Ｈｇｆ凍結乾燥製剤
JP2001029095A (ja) * 1999-07-26 2001-02-06 Mitsui Chemicals Inc Ｎ−アセチルラクトサミン繰り返し構造の含有割合を減少させる方法
EP1246915A2 (en) 1999-12-30 2002-10-09 Maxygen Aps Improved lysosomal enzymes and lysosomal enzyme activators
WO2001060411A1 (en) 2000-02-18 2001-08-23 Kanagawa Academy Of Science And Technology Pharmaceutical composition, reagent and method for intracerebral delivery of pharmaceutically active ingredient or labeling substance
EP1285072A2 (en) * 2000-05-12 2003-02-26 Neose Technologies, Inc. In vitro fucosylation recombinant glycopeptides
WO2002000879A2 (en) * 2000-06-28 2002-01-03 Glycofi, Inc. Methods for producing modified glycoproteins
EP1299535A2 (en) 2000-06-30 2003-04-09 Maxygen Aps Peptide extended glycosylated polypeptides
AU2001283740A1 (en) 2000-08-17 2002-02-25 University Of British Columbia Chemotherapeutic agents conjugated to p97 and their methods of use in treating neurological tumours
WO2002013873A2 (en) 2000-08-17 2002-02-21 Synapse Technologies, Inc. P97-active agent conjugates and their methods of use
EP1930024A3 (en) 2000-09-01 2008-08-06 Chugai Seiyaku Kabushiki Kaisha G-CSF solution formulations having long-term stability
DE60137950D1 (de) 2000-10-02 2009-04-23 Novo Nordisk Healthcare Ag Verfahren zur herstellung vitamin-k-abhängiger proteine
HUP0303251A2 (hu) 2001-02-27 2003-12-29 Maxygen Aps Béta-interferon-szerű molekulák
EP1270551A1 (en) 2001-06-26 2003-01-02 Aventis Pharma Deutschland GmbH Urea derivatives with antiproteolytic activity
ES2516041T3 (es) * 2001-10-10 2014-10-30 Ratiopharm Gmbh Remodelación y glicoconjugación de la hormona del crecimiento humano (hGH)
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
CA2468295C (en) 2001-11-28 2010-08-03 Neose Technologies, Inc. Glycoprotein remodeling using endoglycanases
HUP0402315A3 (en) 2001-12-21 2009-03-30 Novo Nordisk Healthcare Ag Liquid composition of factor vii polypeptides
IL162618A0 (en) 2001-12-21 2005-11-20 Novo Nordisk As Liquid composition of modified factor vii polypeptides
PT1517710E (pt) 2002-06-21 2011-07-08 Novo Nordisk Healthcare Ag Glicoformas do factor vii peguilado
CN1671410B (zh) † 2002-06-21 2010-05-12 诺和诺德医疗保健公司 因子ⅶ多肽的稳定化固体组合物
WO2004082708A2 (en) 2003-03-18 2004-09-30 Novo Nordisk Health Care Ag Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides
WO2004110469A2 (en) 2003-06-13 2004-12-23 Novo Nordisk Health Care Ag Formulations comprising factor viia and a factor vii related polypeptide
EP1654004A2 (en) 2003-08-08 2006-05-10 Novo Nordisk A/S Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides
JP5743368B2 (ja) * 2004-01-08 2015-07-01 ラショファーム ゲーエムベーハー ペプチドのｏ結合型グリコシル化
DE602005019038D1 (de) 2004-05-04 2010-03-11 Novo Nordisk Healthcare Ag O-verknüpfte glykoformen von faktor vii und verfahren zu deren herstellung
CN101268185B (zh) 2005-09-01 2013-03-27 诺沃-诺迪斯克保健股份有限公司 因子ⅶ多肽的疏水作用色谱纯化

Also Published As

Publication number Publication date
EP1745141A1 (en) 2007-01-24
KR20070008645A (ko) 2007-01-17
AU2005243427A1 (en) 2005-11-24
US9023992B2 (en) 2015-05-05
US20080305518A1 (en) 2008-12-11
JP2007536345A (ja) 2007-12-13
ES2339953T5 (es) 2020-05-06
WO2005111225A1 (en) 2005-11-24
ES2339953T3 (es) 2010-05-27
MXPA06012676A (es) 2007-04-02
US10844110B2 (en) 2020-11-24
CA2565414A1 (en) 2005-11-24
EP1745141B2 (en) 2019-09-25
US20180057566A1 (en) 2018-03-01
DE602005019038D1 (de) 2010-03-11
AU2005243427B2 (en) 2010-07-22
BRPI0510295A (pt) 2007-11-06
JP2014088391A (ja) 2014-05-15
ATE455861T1 (de) 2010-02-15
IL178541A0 (en) 2007-02-11
EP1745141B1 (en) 2010-01-20
RU2006138181A (ru) 2008-06-10
JP5826446B2 (ja) 2015-12-02
US20110064719A1 (en) 2011-03-17

Similar Documents

Publication Publication Date Title
NO20065512L (no) O-bundne gykoformer av polypeptider og fremgangsmater for deres fremstilling.
EA200800669A1 (ru) Способ получения гликозилированного интерферона бета
WO2007112082A3 (en) Methods and compositions for the identification of cancer markers
IL184455A0 (en) Silver/water, silver gels and silver-based compositions: and methods for making and using the same
BRPI0618488A2 (pt) proteìnas de fusão de ìntron de fator de crescimento de hepatócito
ECSP056111A (es) Derivados de 2-acilamino-4-feniltiazol, su preparación y aplicación en terapeutica
ZA200703561B (en) Methods and compositions for improving recombinant protein production
TW200621721A (en) Methods of preparing indazole compounds
BRPI0510777A (pt) indazóis substituìdos, composições que os contêm, processo de produção e utilização
GEP20094785B (en) Pyrrolopyrazoles, potent kinase inhibitors
DE602007008874D1 (de) Hemmer der neubildung menschlicher immundefekt-viren
DK2336329T3 (da) Sammensætninger og fremgangsmåder til hæmning af endogene immunglobulingener og til produktion af transgene, humane, idiotypiske antistoffer
BRPI0519046A2 (pt) composição de xampu
WO2006069719A3 (en) Lyophilization of virosomes
ATE504556T1 (de) Herstellung von natriumdiformiat
TW200714277A (en) Methods and compositions for altering cell fuction
EP1893549A4 (en) BIOZIDE CERAMIC COMPOSITIONS, PROCESSES AND MANUFACTURED ARTICLES
TW200602076A (en) O, O'-amidomalonate and N, O-amidomalonate platinum complexes
NO20075275L (no) Nye forbindelser
WO2007144779A3 (en) Compositions comprising porphyra and methods of making and using thereof
UY29859A1 (es) Derivados de 1-amino-isiquinolina,su preparación y su aplicación terapéutica
MX341064B (es) Variantes de la familia il-1.
TW200726763A (en) Novel compound
PL1843778T3 (pl) Kompozycje zawierające galusan epigalokatechiny i hydrolizat białkowy
EE200700041A (et) H?be/vesi, h?beda geelid ja h?bedap?hised kompositsioonid; nende valmistamise ja kasutamise meetodid

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application